New York, USA – May 27, 2026 – Neurodegenerative diseases such as AD and PD continue to pose major challenges to global healthcare due to their complex pathology, progressive nature, and the lack of effective disease-modifying therapies. Despite decades of research, over 90% of CNS drug candidates fail in clinical trials, largely because traditional preclinical models—particularly animal models—often fail to accurately recapitulate human neuronal biology and disease mechanisms.
To address these challenges, Creative Biolabs has launched a new generation of AD and PD in vitro models, leveraging human iPSC-derived neuronal systems and advanced microfluidic 3D culture technologies. These platforms are designed to provide researchers with physiologically relevant tools for dissecting disease mechanisms and screening therapeutic candidates with high fidelity, scalability, and customization.
Creative Biolabs’ AD models replicate the major pathological features of AD, including:
*Amyloid-beta (Aß) aggregation
*Tau hyperphosphorylation
*Synaptic dysfunction
*Neuroinflammatory responses
These models support high-throughput drug screening and mechanistic studies for Alzheimer’s therapeutics.
The Parkinson’s disease platforms are engineered to simulate:
*Dopaminergic neuron degeneration
*Alpha-synuclein aggregation
*Progressive neuronal dysfunction
Researchers can use these models to investigate disease progression and evaluate neuroprotective therapies for Parkinson’s disease.
Human iPSC-Derived Systems for Improved Predictive Accuracy
Unlike conventional animal-based approaches, these new models utilize human induced pluripotent stem cell (iPSC)-derived neurons, offering greater biological relevance to human disease states. Scientists can also integrate astrocytes, microglia, and other CNS cell types to study neuroinflammation, neuron-glia interactions, and synaptic communication.
“Our mission is to provide researchers with advanced in vitro disease models that closely mimic the human brain microenvironment,” said a senior scientist at Creative Biolabs. “By improving the predictive power of AD and PD in vitro models, we aim to help reduce failure rates in neurodegenerative drug discovery.”
Powered by Proprietary 3D Cell Culture Neuronal Chip Technology
The new platforms are supported by Creative Biolabs’ proprietary 3D cell culture chip-neuron technology, a microfluidic system that enhances physiological accuracy through:
*Precise spatial organization of neurons and glial cells
*Controlled microfluidic flow for nutrient and drug transport
*Long-term neurite growth and functional synapse formation
This technology enables more reliable modeling of complex brain microenvironments for neuroscience research.
To explore tailored solutions for CNS drug discovery, disease mechanism studies, and preclinical therapeutic evaluation, please visit https://neuros.creative-biolabs.com.
About Creative Biolabs
Creative Biolabs is a leading provider of disease modeling, microfluidics, and neuroscience research solutions. The company offers innovative platforms and customized services to support pharmaceutical companies, biotech firms, and academic institutions worldwide in advancing CNS drug discovery and translational medicine.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://neuros.creative-biolabs.com
